Core Scientific Enters New Material Agreement, Terminates Prior One and Records Direct Financial Obligation

Core Scientific Inc. reported entry into a material definitive agreement, termination of a material definitive agreement, and creation of a direct financial obligation under Items 1.01, 1.02 and 2.03 of Form 8-K filed with the Securities and Exchange Commission on May 6, 2026.

The filing, submitted under CIK 0001839341, also invoked Item 8.01 for other events and Item 9.01 for financial statements and exhibits. Per the SEC EDGAR record, the company attached exhibits detailing the new contract, the terminated contract and the new obligation.

The scope of the changes centers on Core Scientific's corporate treasury and operational contracting. The new material definitive agreement replaces a prior contract whose termination is now effective. The creation of the direct financial obligation adds a quantified liability to the balance sheet whose exact size is disclosed in the attached exhibits.

No customer counts, bitcoin-hashrate totals or mining-facility counts are stated in the filing.

Operationally the company moves from the prior contractual counterparty and terms to the new counterparty, contract type and payment schedule. The termination ends all future performance obligations under the old agreement on the effective date listed in the exhibits.

The new direct financial obligation becomes due according to the repayment schedule in the executed documents, with interest and covenant terms now binding. These shifts take effect immediately upon execution dates referenced in the filed contracts.

Downstream the company must incorporate the new obligation into its next quarterly report on Form 10-Q or annual report on Form 10-K, updating liquidity and debt footnotes. The terminated agreement removes related revenue or expense recognition going forward.

Standard SEC rules require the company to retain the exhibits for investor review and to evaluate whether the dollar size of the new obligation triggers any separate Form 8-K Item 2.03 disclosure thresholds already satisfied by this filing. No further regulatory approvals are noted as conditions precedent.

This filing constitutes the primary public record of the transactions. Core Scientific last used Form 8-K for similar Items 1.01, 1.02 and 2.03 disclosures in prior capital-market and equipment-supply actions, each followed by updated financial-statement footnotes in subsequent periodic reports.